

CLAIMS

1. A method for inhibiting neuronal cell death, the method comprising treating neuronal cells with a compound of the following Formula (I) or a pharmaceutically acceptable salt thereof *in vitro*:



(I).

2. Use of a pharmaceutical composition containing a compound of the following Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the prevention or treatment of central nervous system diseases:




(I),

wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy,

neurodevelopmental disorder, dementia, autism spectrum disorder, Down’s syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis**.**

3. Use of a health functional food containing a compound of the following Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the prevention or alleviation of central nervous diseases:




(I),


wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down’s syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis**.**

4. A method for inhibiting neuronal cell death, the method comprising treating neuronal cells with a magnesium-serinate compound having the FT-IR spectrum shown in (a), (b) or (c) below or a pharmaceutically acceptable salt thereof *in vitro*:


(a)


COO⁻ Finger print
NH3⁺ band
0.100
0.050
0.000
3800 3600 3400 3200 3000 2800 2600 2400 2200 2000 1800 1600 1400 1200 1000 800 600

(b)


COO⁻ Finger print
NH3⁺ band
0.100
0.000
3800 3600 3400 3200 3000 2800 2600 2400 2200 2000 1800 1600 1400 1200 1000 800 600


(c)


COO⁻ Finger print
NH3⁺ band
0.000
3800 3600 3400 3200 3000 2800 2600 2400 2200 2000 1800 1600 1400 1200 1000 800 600


.

5. Use of a pharmaceutical composition containing a magnesium-serinate compound having the FT-IR spectrum shown in (a), (b) or (c) below or a pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the prevention or treatment of central nervous system diseases**,** wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down’s syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis


(a)



(b)




(c)




6. Use of a health functional food containing a magnesium-serinate compound having the FT-IR spectrum shown in (a), (b) or (c) below or a pharmaceutically acceptable salt thereof as an active ingredient in the manufacture of a medicament for the prevention or alleviation of central nervous diseases,

Wherein the central nervous system diseases are selected from the group consisting of cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis


(a)


COO⁻ Finger print
NH3⁺ band

(b)


COO⁻ Finger print
NH3⁺ band

(c)


COO⁻ Finger print
NH3⁺ band